Sandoz Ag

Biochemie Gesellschaft M.b.h

Biochemie Gesellschaft

Biochemie Gmbh

Nabriva Therapeutics Forschungs Gmbh

Josef Wieser

Johannes Ludescher

Hubert Sturm

Gerd Ascher

Arthur Pichler

Andreas Hotter

Ulrich Griesser

Christoph Langes

Michael Schranz

Werner Heilmayer

Johannes Hildebrandt

Herbert Sturm

Hannes Lengauer

Martin Decristoforo

Katharina Reichenbächer

Gerhard Laus

Nolwenn Martin

Michael Enders

Christian Laschober

Doris Braun

Frtiz Blatter

Richard Tessadri

Robert Ziegert

Volker Kahlenberg

Milica Vukicevic

Ulrich J Griesser

Elfriede Klingler

The present invention relates to a novel process for preparing ceftaroline fosamil as well as to intermediates of this process.

Process for preparing ceftaroline fosamil

The present invention relates to novel crystalline forms of ceftaroline fosamil and to methods for their preparation. Furthermore the present invention relates to the use of the novel forms of ceftaroline fosamil for the preparation of an antibiotic medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel forms of ceftaroline fosamil and to methods of preparing the same. Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel forms of ceftaroline fosamil and &#x3b2;-lactamase inhibitors.

Crystalline forms of ceftaroline fosamil

A crystalline sodium salt of a compound of formula I (INN: Raltegravir) or a hydrate/solvate thereof is disclosed as well as a process for obtaining the same.

Crystalline sodium salt of an HIV integrase inhibitor

The present invention relates to a novel solvate of ivabradine hydrochloride, a process of its preparation and its use for the preparation of specific polymorphic forms of ivabradine hydrochloride.

Acetone solvate of ivabradine hydrochloride

The present invention relates to novel polymorphic forms of Saxagliptin Hydrochloride. The present invention also relates to methods of making polymorphic forms of Saxagliptin Hydrochloride.

Crystal forms of saxagliptin

The present invention relates to a pharmaceutical composition comprising crystalline form Y of posaconazole. The pharmaceutical composition can be used to treat or prevent fungal infections.

Pharmaceutical compositions containing a crystalline form of posaconazole

The present invention relates to crystalline form C of Tigecycline dihydrochloride and to methods for the preparation of the same. Furthermore the present invention relates to the use of crystalline form C of Tigecycline dihydrochloride as an intermediate for the preparation of an anti-infective medicament. Moreover the present invention relates to pharmaceutical compositions comprising crystalline form C of Tigecycline dihydrochloride in an effective amount and to the use of crystalline form C of Tigecycline dihydrochloride as an anti-infective medicament.

Crystalline form C of tigecycline dihydrochloride and methods for its preparation

The present invention is directed to a crystalline form of 2-[6-[3(R)-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-ylmethyl]-benzonitrile, a process for the preparation of said crystalline form and the use thereof in the manufacture of a pharmaceutical composition.

Crystalline form of an organic compound

The present invention relates to crystalline form IV of posaconazole and pharmaceutical compositions comprising the same. The pharmaceutical composition can be used to treat or prevent fungal infections.

Crystalline form of posaconazole

The present invention relates to crystalline forms A and B of Tigecycline hydrochloride and to methods for the preparation of the same. Furthermore the present invention relates to the use of crystalline forms A and B of Tigecycline hydrochloride as intermediates for the formulation of an anti-infective medicament. Moreover the present invention relates to pharmaceutical compositions comprising crystalline form A of Tigecycline hydrochloride in an effective amount and to the use of crystalline form A of Tigecycline hydrochloride as anti-infective medicament.

Crystalline forms of tigecycline hydrochloride

The present invention relates to novel polymorphic forms of aripiprazole and processes for producing them. It further relates to pharmaceutical compositions comprising the novel forms and to the use of the novel forms in the treatment of schizophrenia.

Polymorphic forms of aripiprazole and method

A compound of formula wherein the substituents have various meanings, useful as a pharmaceutical.

Cephalosporins

The present invention relates to a new process for preparing sertraline hydrochloride form II.

Growing community of inventors

Kundl, Austria

Josef Wieser